<DOC>
	<DOCNO>NCT01526720</DOCNO>
	<brief_summary>Type 2 diabetes mellitus complex disease whose clinical phenotype result variable combination genetic nongenetic factor . The aim present study investigate network link phenotype genotype patient newly diagnose type 2 diabetes mellitus . In selected case , clinical evidence hint possible monogenic basis disease , genotype phenotype relative also assess elucidate etiology disease .</brief_summary>
	<brief_title>The Verona Newly Diagnosed Type 2 Diabetes Study</brief_title>
	<detailed_description>The Verona Newly Diagnosed Type 2 Diabetes Study ( VNDS ) ongoing study aim building biobank patient newly diagnose type 2 diabetes mellitus . All patient refer Division Endocrinology Metabolic Diseases University Verona School Medicine , whose diabetes diagnose last six month , ask participate research . The clinical evidence diagnosis type 2 diabetes make review diagnosis confirmed , accord current criterion American Diabetes Association . Patients already treat antidiabetic drug undergo treatment washout least one week metabolic test perform . Among exclusion criterion age &gt; 75 year , non-Italian ancestry , insulin treatment , presence anti-GAD antibody , malignancy , condition severely impair liver and/or kidney function . All subject consume weight-maintaining diet contain 200-250 g carbohydrate/day least three day study . Body weight must stable subject least 1 month study . No subject participate heavy exercise . Each subject give inform write consent participate research , approve Human Investigation Committee Verona City Hospital . Measurements standard clinical phenotype collect patient . Other diabetes relate phenotype may collect determination available . Metabolic test carry two separate day random order . On day , patient admit Metabolic Clinic Research Center 07:30 overnight fast . All study carry quiet , temperature control ( 22° C ) room . On one day oral glucose tolerance test ( OGTT ) ( 75 g ) perform assess beta cell function . On separate day , euglycemic insulin clamp perform assess insulin sensitivity . When age onset distribution disease pedigree suggest potentially monogenic disorder , relatives proband ask participate study allow collection standard clinical information fast blood sample genetic phenotypic determination . -OGTT : For ethical reason , OGTT perform patient present fast plasma glucose high 15 mmol/l . During entire test patient sit comfortable cardiac chair . One teflon ( 21 g ) venous catheter insert antecubital vein blood sample keep patent heparinized normal saline solution . After 30 ' rest establish baseline collect 20 cc blood sample leukocyte DNA extraction , time = 0 ' subject ingest 75 g glucose 300 ml water 5 min . Blood sample measure glucose , C-peptide insulin concentration collect time -10 ' , 0 ' , +15 ' , +30 ' , +45 ' , +60 ' , +90 ' , +120 ' , +150 ' , +180 ' , +210 ' +240 ' , +270 ' +300 ' . Urines collect measure glycosuria . -Euglycemic Insulin Clamp : During entire test patient lie bed . One teflon catheter introduce antecubital vein infusion test substance . Another teflon catheter place retrogradely wrist vein sample arterialize venous blood , accord `` hot box '' technique . After 30 ' rest bed establish baseline , indirect calorimetry ( least 40 ' ) perform . At end calorimetric measure , baseline blood sample collect standard euglycemic insulin clamp carry . After insulin intravenous prime 4.8 pmol/min/m^2 BSA subsequent continuous infusion 240 pmol/min/m^2 BSA , plasma glucose allow decline reach 5.5 mmol/l , glucose clamp start glucose concentration goal 5 mmol/l . The duration glucose clamp least 120 ' , prolong , need , ensure least 60 ' insulin clamp euglycemia patient . Timed blood sample collect measure hormone substrate level . In last 45 ' clamp indirect calorimetry repeat assess substrate oxidation energy production rate . Urine collect measure urea excretion rate . In metabolic test , blood sample collect pre-chilled tube readily spin 1,500 g. Plasma serum specimen store -80° C. -Analytical procedure : Plasma glucose concentration measure duplicate bedside . Serum C-peptide insulin concentration measure chemiluminescence . Glycated hemoglobin serum lipid measure standard in-house method . GAD-antibodies measure immunoradiometry ( CentAK , Medipan , Germany ) , accord manufacturer 's instruction . -Genotyping : A leukocyte DNA sample collect subject DNA extract standard salt method . Genotyping perform RFLP ( Restriction Fragment Length Polymorphism ) , consist PCR ( Polymerase Chain Reaction ) follow proper enzymatic digestion resolution agarose gel . Alternatively , perform assessed high-throughput genotyping Veracode technique ( Illumina Inc , CA ) , apply GoldenGate Genotyping Assay accord manufacturer 's instruction .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Type 2 diabetes mellitus , whose diagnosis make last six month first access Division Endocrinology Metabolic Diseases University Verona School Medicine ; Relatives patient potentially monogenic newly diagnose type 2 diabetes Age &gt; 75 year NonItalian ancestry Insulin treatment Presence antiGAD antibody Malignancies Any condition severely impair liver and/or kidney function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Beta cell function</keyword>
	<keyword>Insulin sensitivity</keyword>
	<keyword>Genetics diabetes</keyword>
</DOC>